Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

Edicotinib

  • Zoom
    Edicotinib
  • Edicotinib
Cat No: 33347
Biochemicals - Kinase Inhibitors
Cayman

Edicotinib is an inhibitor of colony stimulating factor 1 receptor (CSF1R; IC50 = 3.2 nM).{54821} It is selective for CSF1R over KIT and FMS-related tyrosine kinase 3 (FLT3; IC50s = 20 and 190 nM, respectively). Edicotinib (0.1-1,000 nM) reduces CSF1-...

More

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Synonyms:
  • 5-cyano-N-[2-(4,4-dimethyl-1-cyclohexen-1-yl)-6-(tetrahydro-2,2,6,6-tetramethyl-2H-pyran-4-yl)-3-pyridinyl]-1H-imidazole-2-carboxamide
Correlated keywords:
  • 2254450-40-1 JNJ40346527 JNJ527 CD FLT 3 CSF 1 CSF 1R ERK 1/2 N 13 L1236
Product Overview:
Edicotinib is an inhibitor of colony stimulating factor 1 receptor (CSF1R; IC50 = 3.2 nM).{54821} It is selective for CSF1R over KIT and FMS-related tyrosine kinase 3 (FLT3; IC50s = 20 and 190 nM, respectively). Edicotinib (0.1-1,000 nM) reduces CSF1-induced phosphorylation of CSF1R and ERK1/2 in N13 microglia. It reduces spinal motor neuron degeneration and increases the latency to fall in the rotarod test in the P301S mouse model of tauopathy. Edicotinib (15 mg/kg) reduces increases in the colonic weight-to-length ratio, as well as decreases colonic infiltration of macrophages, neutrophils, and CD3+ T cells, in an adoptive T cell transfer-induced mouse model of colitis.{54822} It also reduces the viability of L-1236 Hodgkin lymphoma cells with an IC50 value of 264 nM.{54823}
Size 1 mg
Shipping dry ice
CAS Number 1142363-52-7
Molecular Formula C27H35N5O2
SMILES O=C(C1=NC=C(C#N)N1)NC2=C(C3=CCC(C)(CC3)C)N=C(C4CC(C)(C)OC(C)(C4)C)C=C2
Molecular Weight 461,6
Formulation A crystalline solid
Purity ≥98%
Custom Code 2933.39
UNSPSC code 12352100

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

Search